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ABSTRACT 
The aim of present study was to formulate and evaluate nanoparticles of carvedilol by using different hydrophilic polymers. 
Carvedilol was selected as a suitable drug for gastro- retentive nanoparticles due to its short half life, low bioavailability, high 
frequency of administration, and narrow absorption window in stomach and upper part of GIT. The nano-precipitation method was 
used to prepare nanoparticles so as to avoid both chlorinated solvents and surfactants to prevent their toxic effect on the body. 
Nanoparticles of carvedilol were prepared by using hydrophilic polymers such as HPMC K100M, chitosan, and gelatin. The prepared 
formulations were then characterized for particle size, polydispersity index, zeta potential, loading efficiency, encapsulation 
efficiency and drug-excipient compatibility. The prepared nanoparticulate formulations of carvedilol  with different polymers in 1:1 
ratio have shown particle size in the range of 250.12-743.07 nm, polydispersity index (PDI) in the range of 0.681-1.0, zeta potential 
in the range of -14.2 to +33.2 mV, loading efficiency in the range of 8.74-17.54%, and entrapment efficiency in the range of 55.7%-
74.2%. Nanoparticulate formulation prepared with chitosan in 1:1 ratio showed satisfactory results i.e. average particle size 312.04 
nm, polydispersity index 0.681, zeta potential 33.2 mV, loading efficiency 17.54%, and entrapment efficiency 73.4%. FTIR study 
concluded that no major interaction occurred between  the drug and polymers used in the present study. 
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INTRODUCTION 
The oral route of drug administration is the most 
convenient and commonly used method of drug delivery 
due to their considerable therapeutic advantages such 
as ease of administration, patient compliance, and 
flexibility in formulation. However, this route has 
several physiological problems, such as inability to 
restrain and locate the controlled drug delivery system 
within the desired region of the gastrointestinal tract 
due to variable gastric emptying and motility. 
Furthermore, the relatively brief gastric emptying time 
in humans, which normally means 2-3 hours through 
the major absorption zone, i.e., stomach and upper part 
of the intestine, can result in incomplete drug release 
from the drug delivery system leading to reduced 
efficacy of the administered dose 1-6. These difficulties 
have prompted researchers to design a drug delivery 
system which can stay in the stomach for prolonged and 
predictable period. Several attempts are being made to 
develop a controlled drug delivery system, which can 
provide therapeutically effective plasma drug 
concentration for a longer period, thereby reducing the 
dosing frequency and minimizing fluctuations in plasma 
drug concentration at steady-state by delivering the 
drug in a controlled and reproducible manner. Different 
methodologies have been reported in the literature to 
increase the gastric retention of drugs, like intra-gastric 
floating systems, hydro dynamically balanced systems, 
extendable or expandable, micro porous compartment 
system, microballons, bio-adhesive systems, high-
density systems, and super porous biodegradable hydro 
gel systems. After oral administration, such a dosage 
form would be retained in the stomach for several hours 
and would release the drug there in a controlled and 
prolonged manner, so that the drug could be supplied 
continuously to its absorption sites in the upper 
gastrointestinal tract 7-12. Prolonged gastric retention 
improves bioavailability, reduces drug waste, and 
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improves solubility of drugs that are less soluble in a 
high pH environment. It is also suitable for local drug 
delivery to the stomach and proximal small intestine. 
Gastro retention helps to provide better availability of 
new products with suitable therapeutic activity and 
substantial benefits for patients. The aim of the present 
study was to formulate gastro retentive nanoparticles of 
carvedilol to deliver the drug at a controlled rate to its 
absorption site so that its oral bioavailability can be 
enhanced. Mucoadhesive polymers, such as bovine 
serum albumin, chitosan, and gelatin, were selected to 
prepare gastroretentive nanoparticles as they intensify 
the contact between dosage form and the site of 
absorption, thereby reducing the luminal diffusion 
pathway of the drug (bioadhesion) and lead to 
significant improvements in oral drug delivery13-18.  
Carvedilol is an antihypertensive drug characterized 
by itslow aqueous solubility, a major obstacle in drug 
formulation development to improve its bioavailability. 
To overcome problem of poor aqueous solubility of 
Carvedilol, various approaches have been investigated 
including physical and chemical modifications of the 
drug. 19 
These mucoadhesive polymeric nanoparticles in the 
stomach will offer various advantages such as (i) Longer 
residence time of the dosage form on mucosal tissues 
in the stomach. This will improve absorption of the drug 
and increase the drug bioavailability. (ii) Higher drug 
concentration at the site of adhesion absorption, which 
will create a driving force for the paracellular passive 
uptake. (iii) Immediate absorption from the bioadhesive 
drug delivery system without previous dilution and 
possible degradation in the luminal fluids. 20-23 
MATERIALS AND METHODS 
Table 1: List of Materials used for the study 
S.No. INGREDIENTS SUPPLIER 
1 Carvedilol Yarrow Chem, Mumbai 
2 Hydroxyl propyl methyl 
cellulose K100M 
Ozone International, 
Mumbai. 
3 
Gelatin 
Ozone International, 
Mumbai. 
4 
Chitin 
Loba Chemie Pvt Ltd., 
Mumbai. 
5 
Dimethylsulfoxie  
Sd Fine-Chem Limited, 
Mumbai. 
 
Drug Profile 
Carvedilol is a nonselective β-adrenergic blocking agent 
with α1-blocking activity. It is Carvedilol is used to treat 
high blood pressure and heart failure. It is also used after a 
heart attack to improve the chance of survival if your heart 
is not pumping well. Lowering high blood pressure helps 
prevent strokes, heart attacks, and kidney problems 
Carvedilol is a racemic mixture with the following 
structure: 
 
                           Structural formula of Carvedilol 
Mechanism of action: Carvedilol is a racemic mixture in 
which nonselective β-adrenoreceptor blocking activity is 
present in the S(-) enantiomer and α1-adrenergic blocking 
activity is present in both R(+) and S(-) enantiomers at 
equal potency. Carvedilol has no intrinsic 
sympathomimetic activity19. 
Preparation of Nanoparticles20-22 
Nanoparticles were prepared according to the 
nanoprecipitation method with slight modification. 
Briefly, 200 mg of polymer (HPMC, chitosan, and 
gelatin) was dissolved in 25 ml of acetone separately. 
The carvedilol 100 mg was dissolved in 2 ml of 
dimethylsulfoxide. Both solutions were mixed and then 
50 ml of water was added and stirred for a half hour. 
Acetone was eliminated by evaporation under reduced 
pressure using rotary flash evaporator and the final 
volume of the suspension was adjusted to 10 ml. Then 
this suspension was centrifuged at 15000 rpm at 4oC 
for half an hour. The supernatant was discarded and 
precipitate was washed 3 times with distilled water. The 
nanoparticles thus obtained were dried overnight in 
oven at 60ºC and stored in a desiccator. The prepared 
formulations were characterized for loading efficiency, 
entrapment efficiency, particle size, particle size 
distribution, polydispersity index, zeta potential and 
drug excipient compatibility studies. 
Characterization of Carvedilol Loaded Nanoparticles19-
22 
Loading Efficiency 
Drug content in the preparation was determined by 
extracting the drug from the nanoparticles with 0.1 M 
hydrochloric acid. In this method, the nanoparticles (50 
mg) were stirred in 50 ml of 0.1 M hydrochloric acid 
until dissolved; it was filtered through a Millipore filter 
and the drug content was determined, after suitable 
dilution, at 254 nm by UV spectrophotometry. The 
loading efficiency (L) of the nanoparticles was 
calculated according to Equation 1 
L (%) = (Qn /Wn) × 100                                                  …..(1) 
Where Wn is the weight of the nanoparticles and Qn is 
the amount of drug present in the nanoparticles. 
Entrapment Efficiency 
For determination of drug entrapment, the amount of 
drug present in the clear supernatant after 
centrifugation was determined (w) by UV 
spectrophotometer at 254 nm. A standard calibration 
curve of drug was plotted for this purpose. The amount 
of drug in supernatant was then subtracted from the 
total amount of drug added during the preparation (W). 
Effectively, (W-w) will give the amount of drug 
entrapped in the particles. 
Then percentage entrapment of a drug was calculated 
according to Equation 2 
% Drug Entrapment = (W-w/W) × 100                     …..(2) 
Particle Size, Particle Size Distribution, and Zeta Potential 
The particle size and particle size distribution of the 
formulation was determined by photo correlation 
spectroscopy with a zeta master (Malvern Instruments, 
UK) equipped with the Malvern PCS software. Every 
sample was diluted with distilled water. The surface 
charge (Zeta potential) was determined by measuring 
the electrophoretic mobility of the nanoparticles using a 
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Malvern zeta sizer (Malvern Instruments, UK). Samples 
were prepared by diluting with distilled water. 
Polydispersity Index 
Polydispersity index is a parameter to define the 
particle size distribution of nanoparticles obtained from 
photon correlation spectroscopic analysis. It is a 
dimensionless number extrapolated from the 
autocorrelation function and ranges from a value of 0.01 
for mono dispersed particles and up to values of 0.5-0.7. 
Samples with very broad size distribution have 
polydispersity index values > 0.7. 
Drug-Excipient Compatibility Studies 
The drug excipient compatibility studies were 
performed by using FT-IR spectrophotometer (Perkin 
Elmer). The FT-IR spectra of drug, polymers, and 
formulations were analyzed separately and then 
correlated for incompatibility. 
RESULTS AND DISCUSSION 
The method of nanoprecipitation was used so as to 
avoid both chlorinated solvents and surfactants to 
prevent their toxic effect on the body. All the 
determinations were done in triplicate. 
Drug-loading and entrapment efficiency 
Although drug loading expresses the percent weight of 
active ingredient encapsulated to the weight of 
nanoparticles, entrapment efficiency is the ratio of the 
experimentally determined percentage of drug content 
compared with actual, or theoretical mass, of drug used 
for the preparation of the nanoparticles. The loading 
efficiency depends on the polymer-drug combination 
and the method used. Hydrophobic polymers 
encapsulate larger amounts of hydro phobic drugs, 
whereas hydrophilic polymers entrap greater amounts 
of more hydrophilic drugs. Several formulation 
parameters, such as emulsifier type, weight ratio of 
polymer to drug, and organic to aqueous phase ratio, 
will influence the extent of drug loading. The effect of 
polymer on drug loading efficiency and entrapment 
efficiency are given in Table 1 and shown in Figure 1. 
The values were in the range of 8.74%-17.54% and 
55.7%-74.2%, respectively. Loading efficiency was low 
for gelatin and HPMC nanoparticles (8.74% and 11.43% 
respectively) while high for chitosan nanoparticles 
(17.54%). It was found that the  entrapment efficiency 
were high for the formulations containing chitosan and 
gelatin (73.4% and 74.2% respectively) while low for 
the formulation containing bovine serum albumin 
(55.7%). Loading efficiency may be increased by 
increasing polymer ratio, so that sufficient quantity of 
polymer will be available to entrap the drug present in 
the solution, while less entrapment efficiency may be 
due to hydrophilic nature of carvedilol. 
 
Table 1: Drug loading and Entrapment efficiency 
S.No. Formulation code Drug  : Polymer Loading efficiency ± SD Entrapment efficiency ± SD 
1 NP 1 1:2 11.43 ± 0.2 55.7 ± 0.8 
2 NP 2 1:2 17.54 ± 0.3 75.3 ± 1.0 
3 NP 3 1:2 8.74 ± 0.3 73.4 ± 1.0 
* = Average of three determinations 
 
Figure 1: Effect of polymer on loading and entrapment efficiency. 
 
Particle Size Distribution and Polydispersity Index 
The particle size and particle size distribution are 
critical factors in the performance of nanoparticles, as 
batches with wide particle size distribution show 
significant variations in drug loading, drug release, 
bioavailability, and efficacy. Particle size and particle 
size distribution can be determined using light 
scattering techniques and by scanning or transmission 
electron microscopy. Formulation of nanoparticles with 
a narrow size distribution will be a challenge if emulsion 
cannot be produced with a narrow droplet size 
distribution. As nanoparticles are internalized into cells 
by endocytosis, an increase in particle size will decrease 
uptake and potentially, affect bioavailability of the drug. 
The extent of endocytosis is dependent on the type of 
the target cell. 
The results of prepared nanoparticulate formulations of 
carvedilol with different polymers are given in Table 2 
and shown in Figure 2. The formulations had very high 
polydispersity index (PDI) in the range of 0.681-1.0. 
From the particle size distribution data, it is evident that 
in case of HPMC nanoparticles, mean particle diameter 
was 250.12 nm and major portion of the particles were 
in the range of 200-400 nm, for chitosan nanoparticles 
mean particle diameter was 312.04 nm; and major 
portion of the particles were in range of 200-525 nm. In 
case of gelatin nanoparticles mean particle diameter 
was 743.07 nm and most of the particles were in the 
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range of 480-1200 nm. However, in all the formulations 
contained a minority population of nanoparticles in 
much smaller range. For HPMC, about 10.1% of the 
particles were in the range 15-30 nm, for chitosan about 
7.1% of the particles were in the range 48-90 nm and for 
gelatin 14.1% of the particles were in the range 70-160 
nm. These minority populations are responsible for 
larger over all polydispersity indices of the formulations. 
We are currently exploring the process variables 
affecting the relative amounts of different populations 
with an objective to increase the yield of the particles in 
the smaller range to get much smaller nanoparticles, 
which have greater degree of monodispersity. Such 
nanoparticles can be easily separated from the larger 
sized population by simple methods like filtration. 
 
Table 2: Drug polymer ratio, mean particle size, particle size distribution, poly dispersity index (PDI) and zeta 
potential. 
F. Code Polymer 
Mean Particle 
Size (nm) ± SD 
Size Distribution PDI ± SD 
Zeta Potential 
(mV) ± SD 
NP 1 Ethyl cellulose 250.12 ± 18 10.1% (15-30 nm) 89.9 % (200-400 nm) 1.0 ±0.12 21.7± 1.4 
NP 2 Chitosan 312.04 ± 32 7.8% (48-90 nm) 92.2% (200-525 nm) 0.68 ±0.15 33.2±2.1 
NP 3 Gelatin 743.07 ± 45 14.2% (70-160 nm) 85.8% (480-1200 nm) 0.77±0.14 14.2±1.3 
* = Average of three determination 
 
From the above data it is clear that nanoparticles 
prepared by using chitosan and HPMC exhibited 
reduction in mean nanoparticulate diameter and 
narrower granulometric distribution. But the 
nanoparticles prepared using gelatin as a polymer 
resulted in nanoparticulate population of large particles. 
The higher particle size and polydispersity index may be 
because of absence of emulsifier as the use of emulsifier 
decreases the surface tension between organic phase 
acetone and aqueous phase and leads to the formation 
of smaller solvent droplets, which in turn causes 
decrease in particle size. It also stabilizes newly 
generated surfaces and prevents aggregation of the 
particles as reported by previous researchers. Therefore 
results which were obtained in this study may be 
improved by using increased drug:polymer ratio, using 
different formulation strategy such as desolvation (for 
gelatin and albumin) or counter ion induced aggregation 
(for chitosan and sodium alginate), employing cross 
linking agent followed by neutralizing residual cross 
linking agent with cysteine and high speed stirring. 
 
 
Figure 2: Effect of polymer on mean particle size. 
Zeta Potential 
The measurement of the zeta potential allows 
predictions about the storage stability of colloidal 
dispersions. In general, particle aggregation is less likely 
to occur for charged particles (i.e. high zeta potential) 
due to electric repulsion. Generally, Zeta potential values 
above 30 mV (positive or negative values) lead to more 
stable nanocapsule suspensions because repulsion 
between the particles prevented their aggregation. A 
decrease in zeta potential, i.e. electrostatic repulsion, 
was considered as the cause for the aggregation process. 
The charge on the surface of the nanospheres will 
influence their distribution in the body and the extent of 
uptake into the cells. Because cell membranes are 
negatively charged, there is greater electrostatic affinity 
for positively charged nanoparticles. Therefore, the 
surface of cationic or neutral nanoparticles may be 
modified to confer a positive charge to enhance efficacy. 
The zeta potential values which were in the range of –
14.2 - +21.7 mV, indicates that the colloidal suspension 
may not be stable and may lead to aggregation. Zeta 
potential values can be altered by modifying the major 
components such as surfactants, polymer, and surface 
composition of the nanoparticles, the presence or the 
absence of adsorbed compounds, composition of the 
dispersing phase, mainly the ionic strength, and the pH. 
Drug-Excipient Compatibility Studies 
From the IR data it is clear that functionalities of drug 
have remained unchanged, including intensities of the 
peak. This suggests that during the process of 
formulation polymer has not reacted with the drug to 
give rise to reactant products.  So it is only physical 
mixture and there is no interaction between them which 
is in favor to proceed for formulation. 
CONCLUSION 
Among different nanoparticulate formulations prepared 
by nanoprecipitation method formulation NP 2, with 
chitosan in 1:1 drug: polymer ratio, showed satisfactory 
results; i.e. mean particle size of 312.04 nm (majority of 
the particles were in the range of 200-525 nm), 
polydispersity index of 0.681, zeta potential of 33.2 and 
loading efficiency of 17.54%, and entrapment efficiency 
of 73.4%. FTIR study concluded that no major 
interaction occurred between the drug and polymers 
used in the present study. 
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